ReviewThe lancet. Gastroenterology & hepatology2020
Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?
Review in The lancet. Gastroenterology & hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Global Prevalence of and Factors Associated with Parasitic Coinfection in People Living with Viruses: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2025Pooled it
- The Prevalence and Genotype Distribution of Hepatitis C Virus in Kenya: A Systematic Review and Meta-Analysis.Journal of epidemiology and global health · 2024Pooled it
- Assessing the role of Mac-2 binding protein glycosylation isomer in the management of patients with chronic hepatitis B.World journal of hepatology · 2025Article
- Expanding treatment indications in chronic hepatitis B: Should we treat all patients?Hepatology international · 2025Review
- The Key Importance of Screening Underprivileged People in Order to Achieve Global Hepatitis Virus Elimination Targets.Viruses · 2025Review
- Sero-prevalence of Hepatitis B and C at a Primary Health Care Facility in Ghana.African health sciences · 2024Article
- Global, regional, and national total burden related to hepatitis B in children and adolescents from 1990 to 2021.BMC public health · 2024Article
- Elimination of viral hepatitis: How far are we?: Editorial on "Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study".Clinical and molecular hepatology · 2024Article
- Seroprevalence of hepatitis C, hepatitis B, hiv and syphilis among blood donors at a tertiary care hospital in Mogadishu-Somalia in 2020-2022: a retrospective study.BMC public health · 2024Article
- Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030.Vaccines · 2024Review
- Global temporal trends and projections of hepatitis B-related cirrhosis among adolescents and young adults from 1990 to 2035: an analysis based on the global burden of disease study 2021.Frontiers in public health · 2024Article
- The burden of cirrhosis and other chronic liver diseases due to hepatitis B in children and adolescents: results from global burden of disease study 2019.Frontiers in public health · 2023Article
- World Hepatitis Day 2023: Are we close to the target?The Indian journal of medical research · 2023Article
- Seroprevalence of Hepatitis B, C and D in Vietnam: A systematic review and meta-analysis.The Lancet regional health. Western Pacific · 2022Article
- Article
- European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?JHEP reports : innovation in hepatology · 2021Article
- Elimination of hepatitis C: What would be the practical approach?Clinical and molecular hepatology · 2021Article
- The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.PloS one · 2020Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
In 2019, a Lancet Gastroenterology & Hepatology Commission on accelerating the elimination of viral hepatitis reported on the status of 11 viral hepatitis policy indicators in 66 countries and territories with the heaviest burden by global region. Policies were reported as being either in place, in development, or not in place. This study uses the Commission findings to estimate hepatitis B virus (HBV) and hepatitis C virus (HCV) policy scores and rankings for these 66 countries and territories. We applied a multiple correspondence analysis technique to reduce data on policy indicators into a weighted summary for the HBV and HCV policies. We calculated HBV and HCV policy scores for each country. Countries and territories that received higher scores had more policies in place and in development than did countries with lower scores. The highest scoring country for HBV was Australia, whereas Somalia had the lowest score. For the HCV policy score, Australia and New Zealand had perfect scores, whereas Somalia, Sudan, and Yemen had the lowest scores, all having no policy indicators in place.
Indexed as
Identifiers
32730784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.